News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Ann L. Bullinger, PharmD

Articles by Ann L. Bullinger, PharmD

Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy

ByGirishanthy Krishnarajah, MPH, MBA/MS, PhD,Jee-Yeon K. Lehmann, PhD,Brian Ellman, MBA,Rachel H. Bhak, MS,Maral DerSarkissian, PhD,Deane Leader, Jr, PhD, MBA,Ann L. Bullinger, PharmD,Mei

October 21st 2016

Latest Updated Articles

Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy
Published: October 21st 2016 | Updated:

Trending on AJMC

ACIP Delayed Hepatitis B Vaccine Schedule Vote Amid Safety Controversy

Most Americans Pleased With Health Insurance Options for 2026

Diabetes Tied to Increased Risk of Sudden Cardiac Death

Evaluating Adalimumab Biosimilar Switch Impact on Disease Flares, Tolerability

Experts Say FDA Approval of Perioperative Durvalumab Plus FLOT Sets New Standard of Care for Early-Stage Gastric, GEJ Cancers

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.